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Summary
Inactivation of the von Hippel-Lindau tumor suppressor gene is linked to the development of hereditary (VHL Disease-
associated) and sporadic clear cell carcinoma of the kidney. The VHL gene product, pVHL, targets the heterodimeric
transcription factor HIF for polyubiquitination, and restoration of pVHL function in VHL/ renal carcinoma cells suppresses
their ability to form tumors in nude mice. Here we show that tumor suppression by pVHL can be overridden by a HIF
variant that escapes pVHL control. These studies prove that HIF is a critical downstream target of pVHL and establish that
activation of HIF target genes can promote tumorigenesis in vivo.
Introduction al., 1995; Lonergan et al., 1998; Pause et al., 1997, 1999). These
complexes ubiquitinate the  subunits of the heterodimeric tran-
scription factor called HIF (hypoxia-inducible factor) in the pres-von Hippel-Lindau Disease is a hereditary cancer syndrome that
displays an autosomal dominant pattern of inheritance (Maher ence of oxygen (Cockman et al., 2000; Kamura et al., 2000;
Ohh et al., 2000; Tanimoto et al., 2000). Consequently, normaland Kaelin, 1997; McKusick, 1992). The hallmark feature of this
disorder is the development of blood vessel tumors (heman- cells accumulate HIF only under low oxygen (hypoxic) condi-
tions, whereas cells lacking pVHL contain high levels of HIFgioblastomas) of the central nervous system and retina, often
in association with other tumors such as clear cell carcinomas irrespective of changes in ambient oxygen (Maxwell et al., 1999).
Recent studies have shown that the interaction of pVHL with HIFof the kidney and pheochromocytomas. The VHL gene resides
on chromosome 3p25, and individuals with VHL disease are is governed by oxygen-dependent hydroxylation of conserved
proline residues in HIF by members of the Egl9 family (Bruickgermline VHL/ heterozygotes. Tumors develop in this setting
when the remaining wild-type VHL allele is mutated or lost. and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2001;
Jaakkola et al., 2001; Masson et al., 2001; Yu et al., 2001).Thus, at the molecular level, the VHL gene is a tumor suppressor
gene and conforms to the Knudson two-hit model. In keeping pVHL contains two subdomains called the  domain and
the  domain (Stebbins et al., 1999). The  domain binds to thewith this notion, biallelic VHL inactivation due to somatic muta-
tions is a common feature of nonhereditary clear cell kidney elongins, which in turn bind to Cul2, while the  domain binds
directly to HIF (Ohh et al., 2000). VHL mutations associated withcancers and hemangioblastomas (Brauch et al., 1999; Foster
et al., 1994; Gallou et al., 1999; Gnarra et al., 1994; Kanno et the development of hemangioblastoma or renal cell carcinoma
typically compromise the function of the  domain, the  do-al., 1994; Lee et al., 1998; Shuin et al., 1994, 1999). Furthermore,
restoration of VHL function in VHL/ renal carcinoma cell lines main, or both (Ohh et al., 1999, 2000; Stebbins et al., 1999).
Accordingly, these tumors are characterized by high levels ofsuppresses their ability to form tumors in vivo (Gnarra et al.,
1996; Iliopoulos et al., 1995), and somatic inactivation of VHL HIF as well as the products of HIF-target genes (Gnarra et al.,
1996; Iliopoulos et al., 1996; Krieg et al., 2000; Maxwell et al.,in the mouse causes the development of blood vessel tumors,
which loosely resemble hemangioblastomas (Haase et al., 1999; Siemeister et al., 1996; Wiesener et al., 2001; Wizigmann-
Voos et al., 1995). Some VHL families display a high risk of2001).
The VHL gene product, pVHL, forms a multimeric complex pheochromocytoma without the other stigmata of VHL disease.
Where tested, such families harbor mutant VHL alleles that retainthat contains elongin B, elongin C, Cul2, and Rbx1 (also called
ROC1 or Hrt1) (Duan et al., 1995; Kamura et al., 1999; Kibel et the ability to downregulate HIF (Clifford et al., 2001; Hoffman
S I G N I F I C A N C E
The VHL gene product, pVHL, is frequently mutated in renal carcinoma, and targets HIF for destruction in the presence of oxygen.
Tumor-derived pVHL mutants are defective in this regard. Nonetheless, it is unproven that inhibition of HIF is causally linked to tumor
suppression by pVHL. Here we report that tumor suppression by pVHL can be overridden by a HIF variant that escapes recognition
by pVHL. Thus, inhibition of HIF is necessary for tumor suppression by pVHL. This study shows that activation of HIF-target genes can
promote tumor growth and thus establishes that HIF can behave as an oncogene in vivo. This finding has broad implications, as
most solid tumors contain hypoxic cells, which accumulate HIF.
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Figure 1. Characterization of HIF2 P531A mu-
tant
A: Binding of 35S-labeled wild-type and P531A
HIF2 in vitro translates to immobilized GST-VHL,
elongin B, elongin C (VBC) complexes.
B: Far Western blot analysis of WT8 cells stably
transfected with a plasmid encoding HA-HIF2,
HA-HIF2 P531A, or the empty vector. Cells were
treated with proteasome inhibitor for 8 hr prior
to analysis. Blot was probed with VBC complex.
Note that endogenous HIF2 is not detected un-
der these assay conditions, presumably due to
low abundance.
C: Luciferase activity, corrected for  galactosi-
dase, following transient transfection of U2OS
cells with reporter plasmid containing VEGF pro-
moter upstream of luciferase and plasmids en-
coding the indicated HIF2 species.
et al., 2001). In summary, there is a strong correlation between to another cellular protein that interacts with the  domain in a
manner similar to HIF. If true, the ability to bind to HIF mightthe risk of developing hemangioblastoma and renal cell carci-
be a surrogate for retention of this function. To address thisnoma for a given mutant VHL allele and the ability of its protein
possibility, we have made a HIF variant that retains the abilityproduct to regulate HIF.
to activate HIF-target genes but escapes pVHL control becauseHIF induces the expression of angiogenic factors such as
of a proline to alanine substitution within its pVHL binding motif.VEGF (vascular endothelial growth factor) and PDGF B (platelet-
Introduction of this HIF variant into renal carcinoma cells pre-derived growth factor), as well as mitogenic factors such as
viously rendered pVHL-positive restored their ability to formTGF (de Paulsen et al., 2001; Kourembanas et al., 1990; Se-
tumors in nude mouse xenograft assays. This establishes thatmenza, 1999). Overproduction of angiogenic factors could ex-
inhibition of HIF is necessary for tumor suppression by pVHLplain the hypervascular nature of hemangioblastomas and renal
and demonstrates the previously suspected protumorigenic ef-cell carcinomas. In support of this, forced expression of VEGF
fects of the HIF gene expression program.in murine model systems gives rise to immature blood vessels
that resemble hemangioblastomas, whereas inhibition of VEGF
signaling can inhibit renal cell tumor growth in vivo (Benjamin Results
786-O renal carcinoma cells lack functional pVHL, and overpro-and Keshet, 1997; Drevs et al., 2000). Overproduction of TGF
and its cognate receptor, EGFR, has been described in both duce HIF2 and HIF target genes such as VEGF, PDGF B, and
the GLUT1 glucose transporter (Gnarra et al., 1996; Iliopouloshemangioblastomas and renal cell carcinomas (Atlas et al.,
1992; Bohling et al., 1996; de Paulsen et al., 2001; Knebelmann et al., 1996; Maxwell et al., 1999; Siemeister et al., 1996). 786-O
cells do not contain detectable amounts of HIF1 (Maxwell etet al., 1998; Lager et al., 1994; Lau et al., 1988; Mydlo et al.,
1989; Petrides et al., 1990; Reifenberger et al., 1995; Walke et al., 1999). We previously stably transfected 786-O cells with a
plasmid encoding wild-type pVHL or, as a control, with theal., 1991). TGF acts as a renal epithelial mitogen, and disruption
of TGF/EGFR signaling inhibits renal carcinoma cell prolifera- empty vector. Multiple independent subclones producing wild-
type pVHL (WT clones) were identified and were unable to formtion in vitro and in vivo (Atlas et al., 1992; de Paulsen et al.,
2001; Humes et al., 1991; Petrides et al., 1990; Ramp et al., macroscopic tumors in nude mice, in contrast to the empty
vector transfectants (RC series) or the parental line (Iliopoulos2000).
In summary, both correlative genetic data and biological et al., 1995).
In order to restore activation of HIF target genes in a repre-plausibility suggest that HIF is a critical downstream target of
pVHL with respect to the development of hemangioblastomas sentative WT clone (WT8), we set out to make a HIF2 variant
that would escape recognition by pVHL and yet retain its abilityand renal cell carcinomas. Nonetheless, it has not been formally
proven that downregulation of HIF is either necessary or suffi- to bind to DNA and activate transcription. Mutation of proline
564 to alanine in the pVHL binding motif of HIF1 leads to losscient for tumor suppression by pVHL. For example, it is possible
that tumor suppression by pVHL is linked to its ability to bind of pVHL binding and enhanced stability in vitro and in cellulo
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Figure 2. Introduction of HIF2 P531A into WT8 cells by stable transfection
A and B: 786-O VHL/ human renal carcinoma cells engineered to produce
hemagglutinin (HA)-tagged wild-type pVHL (WT8) were transfected with a
plasmid encoding HA-HIF2 P531A or the empty vector. Following drug
selection, individual colonies were expanded, grown in the presence of 1%
or 21% oxygen, and immunoblotted (IB) with the indicated antibodies.
C: 786-O cells stably transfected with an empty expression plasmid (pRC3)
and representative WT8 clones transfected with a plasmid encoding HA-
HIF2 P531A or the empty vector were grown in 21% oxygen and immu-
noblotted with the indicated antibodies.
(Ivan et al., 2001). In the first set of experiments, the correspond- Figure 3. Proliferation of WT8 stable transfectants producing HIF2 P531A
ing HIF2 mutant (P531A) was made as a radioactive protein A: Stable WT8 subclones tranfected to produce HIF2 P531A or with the
in a rabbit reticulocyte lysate, which contains HIF prolyl hydroxy- empty vector were grown in 96-well plates in the presence of serum. Viable
cell number at the indicated time points after seeding was determined bylase activity, and used in binding studies with immobilized GST-
XTT assay.VHL in complex with elongin B and elongin C. As expected,
B: The indicated WT8 subclones, as well as pVHL-defective pRC3 cells, werewild-type HIF2, but not HIF2 P531A, bound to pVHL (Figure
injected subcutaneously in the flanks of nude mice. Approximately 10 weeks
1A). Likewise, pVHL bound to HA-HIF2, but not HA-HIF2 later, tumors were excised and weighed. The number of tumors analyzed
P531A, in Far Western blot assays of WT8 cells that were engi- is indicated in parentheses. Error bars  one standard error.
neered to produce either of these two proteins and treated with
proteasome inhibitors (Figure 1B). In keeping with this observa-
tion, the half-life of HIF2 P531A was prolonged approximately
puromycin resistance. In parallel, WT8 cells were transfected4-fold relative to wild-type HIF2when introduced into mamma-
with the backbone plasmid. Individual puromycin resistant colo-lian cells (Figure 4C and data not shown). Finally, HIF2 P531A
nies were expanded and analyzed. HIF2 P531A clones 3, 7,retained the ability to activate transcription in cotransfection
and 8 produced readily detectable levels of HA-HIF2 and wereassays using the HIF-responsive VEGF promoter (Figure 1C).
compared to 3 randomly selected empty vector transfectantsThis effect was specific, as it was abrogated by introducing a
(clones 1, 5, and 6) (Figure 2A). The presence of an HA tagsecond mutation within the HIF2 basic HLH domain.
allowed for the identification of the exogenous HIF2 speciesNext, WT8 cells were stably transfected with a plasmid that
encodes hemagglutinin (HA)-tagged HIF2 P531A and confers as well as comparison with the amount of pVHL in the cell by
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anti-HA immunoblot analysis. The total amount of HIF2present
(exogenous and endogenous) was determined by anti-HIF2
immunoblot analysis. The accumulation of HIF2 P531A in the
presence of 21% oxygen despite the availability of excess pVHL
(Figure 2A, lanes 7, 9, and 11) and the minimal variation observed
with changes in oxygen (Figure 2A, compare lanes 7, 9, and 11
with lanes 8, 10, and 12, respectively) further supports that
recognition of HIF2 P531A by pVHL is impaired in intact cells.
The GLUT1 glucose transporter is the product of a HIF-target
gene and is readily monitored by immunoblot analysis. As ex-
pected, HIF2 P531A clones 3, 7, and 8 produced high levels
of GLUT1 (Figure 2B), which were comparable to the levels
observed in 786-O cells lacking pVHL (Figure 2C and data not
shown). Another HIF-target, VEGF, was also activated in the
HIF2 P531A clones as determined by Northern blot analysis
(data not shown).
The presence or absence of pVHL does not grossly affect
the monolayer growth of 786-O cells on plastic in the presence
of serum (Davidowitz et al., 2001; Iliopoulos et al., 1995). Like-
wise, the presence or absence of HIF2 P531A did not substan-
tially alter the proliferation of WT8 cells (Figure 3A). Moreover,
HIF2 did not promote the proliferation of WT8 cells grown
in media containing 0.1% serum (data not shown). Following
subcutaneous injection into nude mice, however, the WT8
clones producing HIF2 P531A formed larger tumors than the
empty vector transfectants, although there was significant clone
to clone variation (Figure 3B). HIF2 P531A clones 7 and 8
reproducibly formed macroscopic tumors which, in the case of
clone 8, approximated those seen in a representative 786-O
clone lacking pVHL (pRC3). The collective difference between
the HIF2 P531A clones and empty vector clones was signifi-
Figure 4. Introduction of HIF2 P531A into WT8 cells by retroviral infectioncant (p 0.04) as determined by the Wilcoxon signed rank test.
The variable rescue of tumor forming capability by HIF2 A and B: pRC3 cells and WT8 cells infected to produce HA-HIF2 P531A or
with the empty vector were grown in the presence of 1% or 21% oxygenP531A among individual WT8 subclones raised the possibility
and immunoblotted (IB) with the indicated antibodies.that genetic heterogeneity arose within the WT8 line before,
C: WT8 cells were retrovirally infected to produce HA-tagged wild-type or
during, or after selection of the individual clones producing P531A HIF2. At the indicated time points following the addition of cyclohex-
HIF2 P531A. To circumvent the need for clonal selection, and amide, cell extracts were prepared and immunoblotted with anti-HA anti-
body.its attendant pitfalls, we next switched to a retroviral-based
approach (Figure 4A). WT8 cells were infected with a retrovirus
that encoded HIF2 P531A and conferred puromycin resis-
tance. In parallel, cells were infected with an empty retrovirus
the empty retrovirus or the retrovirus encoding HIF2 P531Aconferring puromycin resistance alone (“empty vector”). Follow-
(Figure 6). This difference was confirmed by quantification ofing infection, puromycin-resistant cells were pooled and ana-
microvessel density (data not shown). This raises the possibilitylyzed. The accumulation of HIF2 (Figure 4A) and its down-
that angiogenesis following pVHL loss reflects more than dys-stream target GLUT1 (Figure 4B), under normoxic conditions in
regulation of HIF alone. The microvessel densities of the tumorsWT8 cells infected to produce HIF2 P531A, was comparable
formed by the WT8 cells infected with the empty retrovirus orto that observed in the pVHL-defective PRC3 cells. In keeping
the retrovirus encoding HIF2 P531A did not significantly differwith the results obtained with the individual WT8 subclones,
(data not shown), perhaps in keeping with an earlier report thatretroviral introduction of HIF2 P531A did not significantly alter
genetic disruption of HIF1 led to a decrease in tumorigenicitythe proliferation of WT8 cells in vitro (Figure 5A), but fully re-
without altering microvessel density (Ryan et al., 2000). Of note,stored their ability to form tumors in nude mice (Figure 5B).
WT8 tumor cells expressing HIF2 P531A were highly pleiomor-Immunohistochemical analysis of tumors formed by WT8 cells
phic and anaplastic, with significant nuclear atypia and frequentproducing HIF2 P531A confirmed that HIF was transcription-
mitotic figures. Occasional spindle-shaped tumor cells wereally active in vivo, as shown by diffuse, intense, membranous
observed in addition to bizarre, multinucleated, tumor cells.GLUT1 staining, similar to that observed in PRC3 cells (Figure
Histologically, these cells appeared to be more malignant than6). In contrast, GLUT1 staining in the tumors produced by WT8
either the RC3 cells or the WT8 cells.cells infected with the empty retrovirus was restricted to mem-
branous staining in focal patches, which were typically associ-
Discussionated with areas of necrosis. CD31 staining, which marks endo-
In this study we have shown that activation of HIF target genesthelial cells and hence reflects angiogenesis, was increased in
the RC3 tumors compared to the WT8 cells infected with either is sufficient to override the tumor suppressor activity of pVHL
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Figure 5. Proliferation of WT8 cells retrovirally in-
fected to produce HIF2 P531A
A: WT8 cells infected to produce HIF2 P531A
or with the empty vector were grown in 96-well
plates in the presence of serum. Viable cell num-
ber at the indicated time points after seeding
was determined by XTT assay.
B: pVHL-defective pRC3 cells and WT8 cells in-
fected to produce HIF2 P531A or with empty
vector were injected subcutaneously in the
flanks of nude mice. Approximately 10 weeks
later, tumors were excised and weighed. The
number of tumors analyzed is indicated in paren-
theses. Error bars  one standard error.
against human renal carcinoma cells in vivo. This work has sion by pVHL would clearly have implications for the rational
treatment of pVHL-associated tumors with small molecules.implications with respect to pVHL-defective tumors in particular
All cells produce pVHL and at least one HIF family member.and solid tumors in general.
Why pVHL inactivation should be intimately linked to the devel-All pVHL mutants associated with the development of hem-
opment of human hemangioblastoma and renal cell carcinoma,angioblastoma and renal carcinoma examined to date have lost
for example, and not a wide variety of tumors, is unclear. Boththe ability to target HIF for destruction. This correlation, coupled
hemangioblastomas and renal carcinomas are characterizedwith the knowledge that HIF regulates genes involved in angio-
by an admixture of VHL/ tumor cells (derived from a poorlygenesis (such as VEGF) as well as mitogenesis (such as TGF),
characterized CNS “stromal” cell and proximal renal tubularhas led to speculation that downregulation of HIF is linked to
epithelial cell, respectively) and blood vessels that are eitherpVHL tumor suppressor function. Nonetheless, it remained pos-
VHL/ (in VHL disease) or VHL/ (in sporadic tumors) (Chansible that HIF was a stalking horse for an as yet unidentified
et al., 1999; Lubensky et al., 1996; Vortmeyer et al., 1997; Zhu-pVHL binding protein (or proteins). In this regard, several lines
ang et al., 1995, 1996). Immunohistochemical analysis of theseof reasoning suggest that HIF P531A did not promote tumor
tumors is consistent with factors such as TGF acting in angrowth in our assays merely by binding stoichometrically to
autocrine fashion to promote tumor cell proliferation and factorspVHL and preventing it from interacting with other targets. First,
such as VEGF and PDGF B acting in a paracrine fashion tothe binding of HIF2 P531A to pVHL was grossly impaired, as
promote endothelial cell and pericyte proliferation, respectivelydetermined by direct binding assays and by half-life determina-
(Bohling et al., 1996; Brown et al., 1993; Flamme et al., 1998;tion in cells, although it remains possible that some residual
Lager et al., 1994; Lau et al., 1988; Mydlo et al., 1989; Nicol et
interaction takes place via a recently recognized second HIF
al., 1997; Reifenberger et al., 1995; Richard et al., 1998; Strat-
hydroxylation site (Masson et al., 2001). Second, the amount
mann et al., 1997; Walke et al., 1991). In this regard, renal
of pVHL produced by WT cells exceeds by at least 10-fold the epithelial cells appear to be particularly sensitive to the mito-
amount present in normal cells (and hence required for tumor genic effects of TGF, perhaps accounting in part for the tissue-
suppression) (Iliopoulos et al., 1998) and also exceeds the specific effects of pVHL loss (de Paulsen et al., 2001). Mouse
amount of HIF2 P531A produced following retroviral infection. experiments involving either conditional inactivation of VHL or
Therefore, we conclude that downregulation of HIF itself is nec- implantation of cells engineered to produce VEGF suggest that
essary for pVHL tumor suppressor activity, at least as measured inactivation of VHL, and consequent overproduction of VEGF,
in the nude mouse xenograft assays described here. is sufficient to produce blood vessel tumors that have hemangi-
Additional studies will be required to determine if downregu- oblastoma-like features (Benjamin and Keshet, 1997; Haase et
lation of HIF is also sufficient for tumor suppression by pVHL. al., 2001). In the kidney, biallelic VHL inactivation is linked to
In this regard, genetic disruption of HIF1 inhibits tumor growth the development of benign renal cysts. Additional genetic alter-
in model systems as does pharmacological inhibition of some ations are presumably required for conversion to a frank renal
of its targets such as VEGF and TGF/EGFR (Kung et al., 2000; carcinoma. Of note, several studies have linked TGF to renal
Maxwell et al., 1997, 1998; Ryan et al., 2000). Establishing that cyst formation (Lowden et al., 1994; Sweeney et al., 2000).
It is almost certain that pVHL has targets in addition to HIF.inhibition of HIF is necessary and sufficient for tumor suppres-
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Figure 6. Immunohistochemical analysis of WT8
retrovirally infected to produce HIF2 P531A
Representative immunohistochemical analysis
with the indicated antibodies of tumors formed
by pVHL-defective pRC3 cells and WT8 cells in-
fected to produce HIF2 P531A or with empty
vector.
VHL mutations linked to a “pheochromocytoma-only” variant Most solid tumors are characterized by cells that are acutely
of VHL disease encode proteins that retain the ability to ubiquiti- or chronically hypoxic and hence accumulate HIF (Zhong et
nate HIF (Clifford et al., 2001; Hoffman et al., 2001). Such pVHL al., 1999). Indeed, upregulation of HIF has been suggested to
mutants may be defective for recognizing one or more proteins underlie the characteristic changes in tumor cell metabolism
that play important roles in regulating the growth and behavior referred to as the Warburg Effect (Dang and Semenza, 1999;
of adrenal medullary cells. Furthermore, it has not been shown Seagroves et al., 2001). It has been suspected that HIF promotes
that dysregulation of HIF, in any setting, is sufficient to cause tumor growth in vivo, through cell autonomous and nonautono-
tumor growth. In this regard, cutaneous expression of a HIF1 mous changes that would ultimately facilitate growth in a nutri-
variant lacking the HIF oxygen-dependent degradation/pVHL ent-poor, oxygen-depleted microenviroment. Our study pro-
binding domain led to the appearance of functional blood ves- vides direct evidence that activation of HIF target genes does
sels without the features of hemangioblastoma (Elson et al.,
indeed promote tumor cell growth in vivo and that HIF can,2001). Likewise, tumor development is not a feature of condi-
therefore, be viewed as an oncogene.tions characterized by chronic hypoxia, which would lead to
upregulation of HIF. This suggests that the tumor promoting
Experimental procedures
effects of HIF are restricted to certain cell lineages and/or that
tumor development in the setting of pVHL loss is due to dysregu- Plasmids
lation of HIF in addition to loss of other pVHL activities. Finally, The wild-type HIF2 cDNA in pcDNA3.0-HIF2-myc (a generous gift of Dr.
VHL/ renal carcinoma cells harbor additional genetic muta- Steven McKnight) was PCR amplified with Primer A (GCGCGGATCCGC
tions that might also be required for HIF to promote tumor CACCATGACA) and Primer D (GCGCCAATTGTCAGGTGGCCTGGTC), re-
stricted with BamHI and MunI, and ligated into pcDNA3.0-HA and pBABE-growth in this setting.
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Puro-HA cut with BamHI and EcoRI to make pcDNA3.0-HA-HIF2 and Cyclohexamide chase assay
WT8 cells that were retrovirally infected to produce wild-type or P531ApBABE-HIF2, respectively. pcDNA3.0-HA-HIF2 P531A and pBabe-puro-
HIF2 were aliquoted to 35 mm dishes. Once the cells achieved 70%–80%HA-HIF2 P531A were generated by two-step PCR. The HIF2 cDNA was
confluence, cycloheximide was added to a final concentration of 100 g/first amplified with Primer A and Primer B (CATGGGGATATAAGCTGC
ml. At the indicated time points thereafter, cell extracts were prepared andCAGTGTCTC) or Primer C (GAGACACTGGCAGCTTATATCCCCATG) and
immunoblotted with anti-HA antibody.Primer D. Aliquots of these two PCR reactions were then mixed and amplified
with Primers A and D. The resulting PCR product was digested with Bam
Nude mouse xenograft assaysHI/Mun I and ligated with pcDNA3.0-HA vector and pBabe-puro-HA as
Nude mouse xenograft assays were performed as described (Iliopoulos etdescribed above. The HIF2 P531A cDNA in pcDNA3.0-HA-HIF2 P531A
al., 1995). Briefly, cells were released by trypsination and resuspended inwas excised by digestion with BamHI and NotI and ligated into IRES-puro-
PBS. 107 viable cells, as determined by trypan blue staining, were injectedHA cut with these two enzymes to make IRES-puro-HA-HIF2a P531A. To
subcutaneously into the flanks of nude mice. Both flanks were used for eachmake pcDNA3.0-HA-HIF2 P531A bearing a bHLH mutation (conversion of
mouse. One flank was injected with cells producing HIF2 P531A and theamino acids residues 24–29, RCRRSK, to ACAASA) the HIF2 P531A cDNA
other with cells transfected or infected with empty vector. Bidimensionalin pcDNA3.0-HA-HIF2 P531A was first amplified with Primer A/Primer E
measurements were obtained every week and the animals were sacrificed(CTCCGTCTCAGCGCTAGCAGCGCAAGCCGCAGCATC) or Primer F (GAT
10–11 weeks after injection. Autopsy and tumor weight measurements wereGCTGCGGCTTGCGCTGCTAGCGCTGAGACGGAG)/Primer D. Aliquots of
performed by animal care technicians who were unaware of the HIF statusthese two PCR reactions were then mixed and amplified with Primers A and
of the tumors. Tumors were cut in half and fixed in either paraffin or frozenD and ligated with pcDNA3.0-HA vector as described above. All plasmids
in OCT compound for immunohistochemical analysis.were authenticated by DNA sequencing. pGL23-VEGF promoter plasmid
was a kind gift from Dr. Deb Mukhopadhyay. pSV--Gal plasmid was pur-
Immunohistochemistrychased from Promega Corp. (Madison, WI).
Immunohistochemistry was performed as described previously (Loda et al.,
2000). Briefly, 5 m tissue sections of formalin-fixed, paraffin-embeddedCell culture
tumors were stained with a polyclonal rat anti-GLUT-1 antibody (Alpha Diag-786-O renal cell carcinoma subclones stably transfected with either pRc/
nostic Int., San Antonio, TX) (dilution 1:500, incubation time 1 hr at roomCMV empty vector (PRC3) or pRc/CMV-HA-VHL (WT8) (Iliopoulos et al.,
temperature) or monoclonal rat anti-mouse CD31 antibody (PECAM-1; BD1995) were grown in Dulbecco’s modified Eagle’s medium (DMEM) con-
Pharmingen, San Diego, CA) (dilution 1:100, incubation time 1 hr at roomtaining 10% Fetal Clone I (Hyclone) and 1 mg/ml of G418 in the presence
temperature). The reaction was carried out in an automated immunohisto-of 10% CO2 at 37C. WT8 cells were transfected using FuGENE (Roche)
chemistry instrument, the Optimax Plus (BioGenex, San Ramon, CA). Anti-according to the manufacturer’s instructions and selected in the presence
gen-antibody reactions were revealed with standardized development times,of puromycin (1.5 g/ml). Individual drug resistant colonies were isolated
using the streptavidin method with diaminobenzidine (DAB) as substrate.using cloning cylinders and expanded.
Phoenix cells (a generous gift of Dr. Gary Nolan, Dept. of Molecular
Microvessel quantitationPharmacology, Stanford University) were maintained in DMEM containing
Microvessel quantitation was performed as previously described (Ogawa et10% Fetal Clone I in 37C, 10% CO2 incubator.
al., 1995; Weidner et al., 1991). Briefly, the area of highest microvascular
density was selected by scanning at 40	magnification. Then, the microves-
Retroviruses
sel count (MVC) was determined by examining three fields within this area
pBabe-puro-HA-HIF2 (wild-type or P531A), or the backbone vector, were
at 200	 magnification (0.785 mm2 per field). Any CD31-positive endothelial
transfected into the Phoenix packaging cell line using FuGene (Roche) ac-
cell or cluster of cells clearly separated from adjacent microvessels, tumor
cording to the manufacturer’s instructions. Tissue culture supernatant was cells, and other elements of connective tissue was considered a single
harvested 48 hr later, passed though a 0.45 m filter, and added to WT8 countable microvessel. Branching structures were counted as a single vessel
cells in the presence of 4 ug/ml polybrene. Infected cells were selected by unless there was a break in the continuity of the structure. The presence of
growth in the presence of puromycin (1.5 ug/ml). either a lumen or erythrocytes in the lumen was not required to classify a
structure as a vessel. Undefined endothelial cells, which appeared to be
Immunoblot and far Western blot analysis fragments, were not counted as microvessels. For each tumor, the MVC
Cells were lysed in EBC lysis buffer (50 mM Tris [pH 8.0], 120 mM NaCl, was assessed by two independent pathologists who were unaware of the
0.5% Nonidet-P [NP]-40) supplemented with complete protease inhibitor tumor genotypes and the average value of these two counts was taken as
cocktail (Roche Molecular Biochemicals, Mannheim, Germany). Comparable the MVC of the tumor.
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